Kiniksa posts Q3 2025 results via earnings release

Kiniksa Pharmaceuticals International, plc filed a Form 8-K to report that it has released its financial results for the quarter ended September 30, 2025.

Accepted by SEC EDGAR 10/28/2025 - 07:39 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc filed a Form 8-K to report that it has released its financial results for the quarter ended September 30, 2025. The company announced these quarterly results in a press release dated October 28, 2025, which is included as Exhibit 99.1. This filing mainly serves to formally furnish that earnings press release to investors and regulators.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kiniksa Pharmaceuticals (KNSA) report in this Form 8-K?

Kiniksa Pharmaceuticals International, plc filed a Form 8-K to furnish a press release announcing its financial results for the quarter ended September 30, 2025 as Exhibit 99.1.

Which period do the latest KNSA financial results cover?

The financial results discussed relate to Kiniksa Pharmaceuticals’ quarter ended September 30, 2025.

Where can investors find the detailed KNSA quarterly numbers?

The detailed results are contained in the earnings press release furnished as Exhibit 99.1 to this Form 8-K.

When did Kiniksa Pharmaceuticals issue its earnings press release?

Kiniksa Pharmaceuticals issued its earnings press release on October 28, 2025.

Does this KNSA 8-K include financial statements?

The Form 8-K identifies an earnings press release as Exhibit 99.1 under Item 9.01; the detailed financial information is contained in that exhibit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001730430 0001730430 2025-10-28 2025-10-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2025

Kiniksa Pharmaceuticals International, plc

(Exact name of Registrant as Specified in Its Charter)

England and Wales		001-730430		98-1795578
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

23 Old Bond Street, Floor 3

London, W1S 4PZ

England, United Kingdom

(Address of principal executive offices, including zip code)

(781) 431-9100

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Ordinary Shares, $0.000273235 nominal value		KNSA		The Nasdaq Stock Market LLC
				(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On October 28, 2025, Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended September 30, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Earnings Press Release issued by Kiniksa Pharmaceuticals International, plc, dated October 28, 2025
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
Date: October 28, 2025	By:	/s/ Douglas Barry
		Douglas Barry
		Senior Vice President, Chief Legal Officer and Secretary